<DOC>
	<DOCNO>NCT02964572</DOCNO>
	<brief_summary>- Single-center , prospective , active-controlled , open , randomize , 2 arm parallel , interventional , exploratory pilot - Type 2 diabetic patient high cardiovascular risk inadequate glycaemic control metformin-based oral hypoglycemic agent prescribe glimepiride ( comparison group ) empagliflozin ( study group ) 60 day ( plus minus 32 day ) add-on therapy - Changes IL-1beta secretion , serum beta-hydroxybutyrate concentration , NLRP3 inflammasome activity baseline final timepoint assess .</brief_summary>
	<brief_title>Effect Sodium Glucose Co-transporter 2 Inhibitor Inflammatory Cytokine Type 2 Diabetes</brief_title>
	<detailed_description>First among cardiovascular ( CV ) end point trial glucose-lowering agent , EMPA-REG OUTCOME trial-using 10 25 mg/day SGLT2 inhibitor empagliflozin placebo 7,020 patient T2DM increase CV risk-reported 14 % reduction major CV event mark relative risk reduction CV mortality ( 38 % ) , hospitalization heart failure ( 35 % ) , death cause ( 32 % ) median time period 2.6 year . Though result raise possibility mechanism observe trial-modest improvement glycemic control , small decrease body weight , persistent reduction blood pressure uric acid level-may play , 's clearly know yet . The inflammatory nature atherosclerosis well establish . We hypothesize empagliflozin might inhibitory effect inflammasome activity macrophage , thus contribute cardioprotective effect diabetes . - Single-center , prospective , active-controlled , open , randomize , 2 arm parallel , interventional , exploratory pilot - Type 2 diabetic patient high cardiovascular risk inadequate glycaemic control metformin-based oral hypoglycemic agent prescribe glimepiride ( comparison group ) empagliflozin ( study group ) 60 day ( plus minus 32 day ) add-on therapy - Changes IL-1beta secretion , serum beta-hydroxybutyrate concentration , NLRP3 inflammasome activity baseline final timepoint assess</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Age ≥19 year inadequate glycaemic control : HbA1c ≥7 % fast glucose ≥130 mg/dl random glucose ≥180 mg/dl High risk cardiovascular event define presence ≥1 follow : 1 . History myocardial infarction 2 . Evidence multivessel coronary artery disease 3 . Evidence singlevessel coronary artery disease positive noninvasive stress test ischemia history hospitalization unstable angina 4 . History stroke 5 . Evidence occlusive peripheral artery disease 6 . Evidence carotid atherosclerosis 7 . Metabolic syndrome Healthy volunteer Type 1 diabetes Organ transplantation Pregnant woman eGFR &lt; 45 Cortisol growth hormone deficiency , pituitary disease Gastric surgery Hematologic disorder Active cancer</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>